Ex-Recursion director to sell 77K RXRX shares
RECURSION PHARMACEUTICALS, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
RECURSION PHARMACEUTICALS, INC. (RXRX) is the issuer of Class A common stock covered by this Rule 144 notice. Former director Christopher C. Gibson has filed to sell 77,290 Class A shares through Fidelity Brokerage Services LLC, with an aggregate market value of $262,013.10, listed on NASDAQ. The notice also lists multiple Class A share sales over the prior three months by Gibson, the Gibson Family Trust, and Lahwran-3 LLC, for which Gibson is an authorized individual or trustee.
Key Figures
Key Terms
Rule 144 regulatory
attorney-in-fact regulatory
aggregate market value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What securities are being proposed for sale under Rule 144 for RXRX?
Who is the selling security holder in this RXRX Form 144 filing?
Are any entities associated with Christopher C. Gibson included in the RXRX past 3-month sales?
When is the stated date of sale and notice date for this RXRX Form 144?
AI-generated analysis. How Rhea-AI works. Not financial advice.